An easy way of publishing your relevant EU press releases.

A DIGITAL FUTURE FOR VALUE ADDED MEDICINES – IQVIA publication shares the future of the sector


24 Sep 2019


Health & Consumers
The value added medicines sector group of Medicines for Europe welcomes the publication from IQVIA’s Thought Leadership “A Digital Future for Value Added Medicines”.
The publication provides valuable insights on the drivers behind the sector, its challenges and what the future holds for value added medicines. The importance of regulatory and payer environments to evolve pragmatically and stimulate the development of this innovation as well as seizing the future digital endeavours are especially insightful.
Adrian van den Hoven, Director General of Medicines for Europe, commented: “IQVIA’s publication shows the future opportunity that value added medicines will bring to patients, healthcare communities and society. The report highlights important global trends and therapy areas that will shape the future of the sector. We encourage governments and the healthcare community to work together to optimise regulatory and reimbursement decision-making processes to take advantage of the opportunity of value added medicines!”
About the Value Added Medicines Group
The Value Added Medicines Group is a sector group of Medicines for Europe which aims at optimizing, rethinking and reinventing medicines based on known molecules and by bringing untapped innovation to improve care delivery. The Value Added Medicines Group adopts a complementary perspective compared to the other Medicines for Europe sector groups: by tackling the targeted portion of patients’ needs that remain unmet to this day, delivering additional improvement to the healthcare community as a whole.
About Medicines for Europe
Medicines for Europe represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe, and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information please follow us at and on Twitter @medicinesforEU.